2016 Yildiz M, Brugger F, Kästle N, Tettenborn B. Neurocognitive impairment and corpus callosum atrophy in multiple sclerosis. Neurology, Psychiatry and Brain research. In Press. 2014 Yildiz M, Tettenborn B, Radue EW, Bendfeldt K, Borgwardt S. Association of cognitive impairment and lesion volumes in multiple sclerosis - A MRI study. Clin Neurol Neurosurg. 2014 Dec;127:54-8. doi: 10.1016/j.clineuro.2014.09.019. Epub 2014 Oct 14.
2014 Ulmer A, Dietz K, Hodak D, Polzer B, Scheitler S, Yildiz M, Schanz S, Röcken M, Garbe C, Breuninger H, Fierlbeck G, Klein CA: Quantitative measurement of melanoma spread in sentinel lymph nodes and survival. PLOS Medicine. IN PRESS
2013 Yildiz M, Tettenborn B, Borgwardt S. Trajectory of fatigue in natalizumab treated multiple sclerosis patients. Clinical Neurology and Neurosurgery.115 902– 903.
2012 Yildiz M. Slower Walking Speed Limits the Activities of Daily Living of Multiple Sclerosis Patients. International Journal of Clinical Practice. 2012 Nov; 66(11):1188-94.
2011 Yildiz M, Borgwardt S, Berger G. Parietal lobes in schizophrenia: Do they matter? Schizophrenia Research and Treatment. Volume 2011, Article ID 581686, doi:10.1155/2011/581686
2011 Haltmeier S, Yildiz M, Müller S, Anliker MD, Heinzerling L. Contact dermatitis induced by glatiramer acetate. Mult Scler. 2011 Nov;17(11):1390-2. Epub 2011 Jul 52011 Yildiz M, Tettenborn B. Fatigue und Multiple Sklerose. Info Neurologie&Psychiatrie 4/2011.
2011 Yildiz M, Tettenborn B, Putzki N: 25-hydroxyvitamin D Levels in Swiss Multiple Sclerosis Patients. Swiss Med Wkly. 2011; 141: w13192.
2011 Yildiz M, Tettenborn B, Putzki N: Multiple Sclerosis associated Fatigue during Disease Modifying Treatment with Natalizumab, Interferon-beta and Glatirameracetate. Eur Neurol
2011; 65: 231–232.2010 Yildiz M, Tettenborn B, Putzki N. Natalizumab and Beyond. Eur Neurol. 2010 Sep 4; 64(4): 236-240
2007 Yildiz M, Pflüger M, Riecher-Rössler A and Berger G: Aneurysms of pericallosal cerebral artery haemorrhage with consecutive psychosis. Australian and New Zealand Journal of Psychiatry 2007; 41(6): 554
2007 Berger G, Yildiz M, Aston J, Gschwandtner U, Riecher-Rössler A: Früherkennung psychotischer Störungen – ein praktischer Leitfaden. The Medical Journal 2007; 2: 29-32
2007 Yildiz M, Borgwardt S, Fusar-Poli P: Is a DNA sequence variation of the gene protocadherin Y a possible explanation for the six fold higher risk to develop schizophrenia in Moroccan males? Medical Hypotheses 2007; 69(3):694
2007 Yildiz M, Borgwardt S: Apoptosis may be the main cause for acceleration of normal changes in adolescent brain structure, leading to the onset of psychosis. Medical Hypotheses. 2008. 70(3): 706-7
2011 Yildiz M. Slower Walking Speed Limits the Activities of Daily Living of Multiple Sclerosis Patients. Submitted for European Neurological Society 21st Meeting 2011 in Lisbon, Portugal
2011 Calabrese P, Annoni JM, Baumann C, Baumann A, Haefeli T, Kamm C, Koch M, Yildiz M, Müri R: Screening for cognitive impairment in Multiple Sclerosis - Proposal of an expert-based two-step approach. 185th annual meeting of the Swiss Neurological Society 2011 in Lucerne, Switzerland
2011 Yildiz M, Tettenborn B, Putzki N: Multiple sclerosis associated fatigue during disease modifying treatment with natalizumab, interferon-beta and glatirameracetate: 1 year follow-up. American Academy of Neurology 63rd Annual Meeting 2011 in Honolulu, Hawaii, USA
2010 Yildiz M, Tettenborn B, Putzki N: Multiple Sclerosis associated Fatigue during Disease Modifying Treatment with Natalizumab, Interferon-beta and Glatirameracetate. Presentation in ECTRIMS 2010 in Goteborg, Sweden
Strictly necessary cookies guarantee functions without which this website would not function as intended. As a result these cookies cannot be deactivated. These cookies are used exclusively by this website and are therefore first party cookies. This means that all information stored in the cookies will be returned to this website.
Functional cookies enable this website to provide you with certain functions and to store information already provided (such as registered name or language selection) in order to offer you improved and more personalized functions.
Performance cookies gather information on how a web page is used. We use them to better understand how our web pages are used in order to improve their appeal, content and functionality.
Marketing / Third Party Cookies originate from external advertising companies (among others) and are used to gather information about the websites visited by you, in order to e.g. create targeted advertising for you.